



40-

Компания была основана в 1982 году в районе Пенджаб, Индия, с целью производства активных фармацевтических ингредиентов.

Компания является производителем активных фармацевтических ингредиентов (API), который производит сырье для нескольких ведущих компаний фармацевтической промышленности, которые используют эти продукты для изготовления лекарств.

Они поставляют продукцию таким компаниям, как Pfizer, Abbott, Cipla, Glenmark, Macleods, Aristo и т. Д.

Компания предлагает широкий спектр от антибиотиков, витаминов, антикоагулянтов до офтальмологических продуктов. Бизнес также проверяется несколькими организациями, такими как ISO, ZED, а также GMP регулирующими органами в Индии и за рубежом.

Исследование

Компания работает над запатентованной технологией рекомбинантного белка, которая работает на основе новой целевой терапии и не дает побочных эффектов. В настоящее время операции сосредоточены на новых молекулах высокого класса.

Исследования

В настоящее время компания проводит экспериментальные исследования методов омоложения стволовыми клетками, которые также обещают будущее лекарств без каких-либо побочных эффектов.

Биотехнологии

Компания занимается проведением значительных биотехнологических исследований в области целевых терапевтических белков человека. Его текущая исследовательская работа направлена на создание нового препарата, который, одновременно излечивая пациентов с астмой и аллергией, может также воздействовать на мастоцитоз и базофильный лейкоз.

Команда

Команда состоит из 100 просвещенных людей, химиков, фармацевтов, биотехнологов, контролеров качества, экспертов по исследованиям и разработкам, персонала складского хозяйства.

Рынок: 65% Индия / 35% Остальной мир / Европа

TARGET PRICE

\$40,000,000

GROSS REVENUE

\$25,000,000

EBITDA

\$3,000,000

BUSINESS TYPE

Производственные компании

ESTABLISHED

1989

SUPPORT & TRAINING

12 месяцев

COUNTRY

Индия

BUSINESS ID

L#20210013

Продукты: 25 продуктов OEM / фармацевтическое сырье для активных ингредиентов

Наиболее продаваемые: антибиотики.

Стандарты: ISO9001, стандарты EC (без FDA)

Скорость роста: 20% + / год

Размер: 100+ сотрудников

Менеджмент: инженер-химик

Финансы: выручка 25 млн долл. / EBITDA 3 млн долл. США

Customers:



Abbott

CiplaHealth
improving lives, every day



glenmark
A new way for a new world

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

www.mergerscorp.com



© 2024 MergersCorp M&A International. All rights reserved.

© 2024 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.



WWW.MERGERSCORP.COM